23andMe Holding Co. (OQ:ME)

Business Focus: Medical & Diagnostic Laboratories

Sector:  Healthcare Industry:  Healthcare Facilities & Services
See Regulatory Filings on SEC
Company Contact
Address: 349 Oyster Point Boulevard
Tel: N/A
Website: https://investors.23andme.com
IR: See website
Key People
Anne Wojcicki
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Joseph Selsavage
Interim Chief Financial Officer, Chief Accounting Officer
Kathy L. Hibbs
Chief Administrative Officer, Company Secretary
Business Overview
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients' lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
Financial Overview
For the nine months ended 31 December 2023, 23andMe Holding Co. revenues decreased 25% to $155.6M. Net loss increased 85% to $457.9M. Revenues reflect Research services segment decrease of 60% to $16.5M, Consumer services segment decrease of 15% to $111.7M, United Kingdom segment decrease of 56% to $20.7M, United States segment decrease of 15% to $124.7M.
Employees: 769 as of Mar 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $30.48M as of Dec 31, 2023
Annual revenue (TTM): $247.99M as of Dec 31, 2023
EBITDA (TTM): -$296.84M as of Dec 31, 2023
Net annual income (TTM): -$521.97M as of Dec 31, 2023
Free cash flow (TTM): -$194.28M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 482,916,636 as of Jan 31, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.